Korro Bio Inc (KRRO)

Currency in USD
13.680
-0.250(-1.79%)
Closed·
13.420-0.260(-1.90%)
·
KRRO is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
13.33014.069
52 wk Range
5.20455.890
Key Statistics
Prev. Close
13.93
Open
13.87
Day's Range
13.33-14.069
52 wk Range
5.204-55.89
Volume
77.44K
Average Vol. (3m)
247.18K
1-Year Change
1.6345%
Book Value / Share
10.55
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
KRRO Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
20.000
Upside
+46.20%
Members' Sentiments
Bearish
Bullish
ProTips
Analysts anticipate sales growth in the current year

Korro Bio Inc News & Analysis

Show more

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Neutral
Technical Indicators
Sell
Moving Averages
Strong Buy

Korro Bio, Inc., a biopharmaceutical company, engages in the discovering, developing, and commercializing of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases in the United States. The company’s lead product candidate is KRRO-121 for the treatment for hyperammonemia. It uses its RNA editing platform, Oligonucleotide Promoted Editing of RNA to generate differentiated RNA editing product candidates. The company is also developing programs for Parkinson’s disease, Amyotrophic lateral sclerosis, severe drug-associated anesthetics, and other pain indications. Korro Bio, Inc. has a collaboration agreement with Novo Nordisk A/S to treat cardiometabolic diseases. Korro Bio, Inc. was founded in 2018 and is based in Cambridge, Massachusetts.

Korro Bio Inc SWOT Analysis


Future Prospects
Learn about Korro's pipeline expansion, including a second candidate for rare metabolic disorders and collaboration with Novo Nordisk on cardiometabolic programs
Competitive Edge
Explore Korro's potential advantages: full economic rights to lead program, superior preclinical data, and lower enterprise value compared to peers
Financial Landscape
$139M cash position extends runway to 2027. Analyst price targets range from $25 to $180, with current market cap at $302.86M, below some competitors
RNA Editing Pionee
Korro Bio leads in ADAR technology for genetic disorders, with AATD treatment KRRO-110 in Phase 1/2a trials and a versatile platform for multiple indications
Read full SWOT analysis

Compare KRRO to Peers and Sector

Metrics to compare
KRRO
Peers
Sector
Relationship
P/E Ratio
−1.3x−0.9x−0.5x
PEG Ratio
−0.09−0.180.00
Price / Book
1.1x0.7x2.6x
Price / LTM Sales
15.2x32.3x3.2x
Upside (Analyst Target)
66.7%819.5%45.7%
Fair Value Upside
Unlock19.4%4.8%Unlock

Analyst Ratings

7 Buy
2 Hold
0 Sell
Ratings:
9 analysts
Overall Consensus
Buy

Analysts 12-Month Price Target:

Average 20.000
(+46.20% Upside)
Firm
ArticlePositionPrice TargetUpside / DownsideFrom Price TargetActionDate
Cantor Fitzgerald
Buy22.00+60.82%-MaintainMar 13, 2026
Raymond James
Buy23.00+68.13%-UpgradeMar 13, 2026
Clear Street
Buy18.00+31.58%10.00UpgradeFeb 18, 2026
William Blair
Buy---UpgradeFeb 17, 2026
H.C. Wainwright
Buy20.00+46.20%-UpgradeJan 29, 2026

Earnings

Latest Release
Mar 12, 2026
EPS / Forecast
-5.32 / -2.42
Revenue / Forecast
1.29M / --
EPS Revisions
Last 90 days

KRRO Income Statement

People Also Watch

18.37
KVYO
+8.44%
194.20
VICR
+2.16%
62.930
AXTI
-6.49%
34.84
PACS
+5.13%
19.080
CORZ
+2.14%

FAQ

What Is the Korro Bio (KRRO) Stock Price Today?

The Korro Bio stock price today is 13.680 USD.

What Stock Exchange Does Korro Bio Trade On?

Korro Bio is listed and trades on the Nasdaq Stock Exchange.

What Is the Stock Symbol for Korro Bio?

The stock symbol for Korro Bio is "KRRO."

What Is the Korro Bio Market Cap?

As of today, Korro Bio market cap is 197.300M USD.

What Is Korro Bio's Earnings Per Share (TTM)?

The Korro Bio EPS (TTM) is -12.481.

From a Technical Analysis Perspective, Is KRRO a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Buy.

How Many Times Has Korro Bio Stock Split?

Korro Bio has split 1 times.

How Many Employees Does Korro Bio Have?

Korro Bio has 58 employees.

What is the current trading status of Korro Bio (KRRO)?

As of Apr 16, 2026, Korro Bio (KRRO) is trading at a price of 13.680 USD, with a previous close of 13.930 USD. The stock has fluctuated within a day range of 13.330 USD to 14.069 USD, while its 52-week range spans from 5.204 USD to 55.890 USD.

What Is Korro Bio (KRRO) Price Target According to Analysts?

The average 12-month price target for Korro Bio is 20.000 USD, with a high estimate of 30 USD and a low estimate of 8 USD. 7 analysts recommend buying the stock, while 0 suggest selling, leading to an overall rating of Buy. The stock has an +46.20% Upside potential.

What Is the KRRO Premarket Price?

KRRO's last pre-market stock price is 13.884 USD. The pre-market share volume is 60.000, and the stock has decreased by -0.046, or -0.330%.

What Is the KRRO After Hours Price?

KRRO's last after hours stock price is 13.420 USD, the stock has decreased by -0.260, or -1.900%.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers.
© 2007-2026 - Fusion Media Limited. All Rights Reserved.